- Home
- KNSA
as 05-09-2025 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.0B | IPO Year: | 2018 |
| Target Price: | $38.00 | AVG Volume (30 days): | 677.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.38 - $28.56 | Next Earning Date: | 04-29-2025 |
| Revenue: | $481,166,000 | Revenue Growth: | 59.45% |
| Revenue Growth (this year): | 37.21% | Revenue Growth (next year): | 1.53% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moat Ross | KNSA | CHIEF COMMERCIAL OFFICER | May 1 '25 | Sell | $28.00 | 10,122 | $283,416.00 | 9,415 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Apr 29 '25 | Sell | $26.79 | 88,395 | $2,347,335.10 | 27,009 | |
| Moat Ross | KNSA | CHIEF COMMERCIAL OFFICER | Apr 29 '25 | Sell | $26.62 | 87,269 | $2,265,339.03 | 9,415 | |
| Moat Ross | KNSA | CHIEF COMMERCIAL OFFICER | Apr 21 '25 | Sell | $20.29 | 18,259 | $370,475.11 | 9,415 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Apr 14 '25 | Sell | $20.47 | 12,000 | $245,811.55 | 83,784 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 20 '25 | Sell | $23.11 | 15,944 | $368,465.84 | 27,009 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 16 '25 | Sell | $23.10 | 20,343 | $469,923.30 | 27,009 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 12 '25 | Sell | $22.25 | 36,372 | $809,277.00 | 27,009 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Mar 12 '25 | Sell | $22.45 | 9,051 | $203,194.95 | 26,528 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Mar 10 '25 | Sell | $21.06 | 12,409 | $261,333.54 | 83,784 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing
MT Newswires
8 days ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,347,335, According to a Recent SEC Filing
Simply Wall St.
9 days ago
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates
Simply Wall St.
9 days ago
US High Growth Tech Stocks To Watch In April 2025
GlobeNewswire
10 days ago
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
Simply Wall St.
10 days ago
An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued
MT Newswires
10 days ago
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating
MT Newswires
11 days ago
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.